{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T11:16:09Z","timestamp":1790162169936,"version":"4.1.0"},"reference-count":33,"publisher":"Public Library of Science (PLoS)","issue":"11","license":[{"start":{"date-parts":[[2025,11,19]],"date-time":"2025-11-19T00:00:00Z","timestamp":1763510400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS One"],"abstract":"<jats:sec id=\"sec001\">\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Multiple CDK4\/6 inhibitors have been approved for the treatment of HR\u2009+\u2009\/HER2- advanced breast cancer. Nevertheless, there is currently a scarcity of safety reports on CDK4\/6 inhibitors within large sample cohorts.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"sec002\">\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We employed a disproportionality analysis of the FAERS database to detect safety signals for the three marketed CDK4\/6 inhibitors (palbociclib, abemaciclib, and ribociclib). We retrieved pertinent reports from 2004 Q1 to 2023 Q3. Four asymmetric analyses were utilized to assess signals.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"sec003\">\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>A total of 459 positive signals were obtained at the preferred term level (146 positive signals for palbociclib, 68 positive signals for abemaciclib, 245 positive signals for ribociclib). Palbociclib-related adverse events were commonly fatigue, white blood cell count decreased, alopecia. Abemaciclib-related adverse events were commonly diarrhea, decreased appetite, dehydration. Ribociclib-related adverse events were commonly neutropenia, white blood cell count decreased and decreased immune responsiveness. Unexpected adverse events related to palbociclib included hot flush, bone marrow failure. Unexpected adverse events related to abemaciclib included myelosuppression, dehydration, and cystatin C increased. Unexpected adverse events related to ribociclib included decreased immune responsiveness, pleural effusion, atrioventricular conduction time shortened.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"sec004\">\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Our research corroborates the typical adverse events linked to CDK4\/6 inhibitors while highlighting potential safety concerns in their real-world clinical application.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1371\/journal.pone.0336767","type":"journal-article","created":{"date-parts":[[2025,11,19]],"date-time":"2025-11-19T18:26:29Z","timestamp":1763576789000},"page":"e0336767","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":3,"title":["Safety assessment of cyclin-dependent kinase 4\/6 inhibitors and comparison of time to adverse events"],"prefix":"10.1371","volume":"20","author":[{"ORCID":"https:\/\/orcid.org\/0009-0005-5065-8278","authenticated-orcid":true,"given":"Siqi","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Renmin","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yingzi","family":"Xia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dingwen","family":"Cao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2025,11,19]]},"reference":[{"issue":"3","key":"pone.0336767.ref001","first-page":"209","article-title":"Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"71","author":"H Sung","year":"2021","journal-title":"CA Cancer J Clin"},{"issue":"10074","key":"pone.0336767.ref002","doi-asserted-by":"crossref","first-page":"1134","DOI":"10.1016\/S0140-6736(16)31891-8","article-title":"Breast cancer","volume":"389","author":"N Harbeck","year":"2017","journal-title":"Lancet"},{"issue":"9","key":"pone.0336767.ref003","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1038\/nrclinonc.2015.99","article-title":"Challenges in the management of advanced, ER-positive, HER2-negative breast cancer","volume":"12","author":"CD Hart","year":"2015","journal-title":"Nat Rev Clin Oncol"},{"issue":"5","key":"pone.0336767.ref004","first-page":"480","article-title":"Systemic therapy for hormone receptor-positive\/human epidermal growth factor receptor 2-negative early stage and metastatic breast cancer","volume":"73","author":"LA Huppert","year":"2023","journal-title":"CA Cancer J Clin"},{"issue":"10226","key":"pone.0336767.ref005","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1016\/S0140-6736(20)30165-3","article-title":"Cyclin-dependent kinase 4 and 6 inhibitors for hormone receptor-positive breast cancer: past, present, and future","volume":"395","author":"LM Spring","year":"2020","journal-title":"Lancet"},{"issue":"5","key":"pone.0336767.ref006","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1016\/j.celrep.2015.12.094","article-title":"Metabolic reprogramming of pancreatic cancer mediated by CDK4\/6 inhibition elicits unique vulnerabilities","volume":"14","author":"J Franco","year":"2016","journal-title":"Cell Rep"},{"issue":"7658","key":"pone.0336767.ref007","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1038\/nature22797","article-title":"The metabolic function of cyclin D3-CDK6 kinase in cancer cell survival","volume":"546","author":"H Wang","year":"2017","journal-title":"Nature"},{"issue":"9","key":"pone.0336767.ref008","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1080\/14740338.2017.1351541","article-title":"Breast cancer treatment-induced cardiotoxicity","volume":"16","author":"S Martel","year":"2017","journal-title":"Expert Opin Drug Saf"},{"issue":"1","key":"pone.0336767.ref009","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.tcm.2018.06.001","article-title":"Update on cardio-oncology: novel cancer therapeutics and associated cardiotoxicities","volume":"29","author":"A Guha","year":"2019","journal-title":"Trends Cardiovasc Med"},{"issue":"1","key":"pone.0336767.ref010","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1007\/s12282-017-0818-4","article-title":"Hematological adverse effects in breast cancer patients treated with cyclin-dependent kinase 4 and 6 inhibitors: a systematic review and meta-analysis","volume":"25","author":"L Kassem","year":"2018","journal-title":"Breast Cancer"},{"issue":"4","key":"pone.0336767.ref011","doi-asserted-by":"crossref","DOI":"10.1136\/esmoopen-2020-000774","article-title":"Real-world clinical outcome and toxicity data and economic aspects in patients with advanced breast cancer treated with cyclin-dependent kinase 4\/6 (CDK4\/6) inhibitors combined with endocrine therapy: the experience of the Hellenic Cooperative Oncology Group","volume":"5","author":"E Fountzilas","year":"2020","journal-title":"ESMO Open"},{"key":"pone.0336767.ref012","doi-asserted-by":"crossref","DOI":"10.1177\/1758835918793326","article-title":"Management of adverse events during cyclin-dependent kinase 4\/6 (CDK4\/6) inhibitor-based treatment in breast cancer","volume":"10","author":"M Thill","year":"2018","journal-title":"Ther Adv Med Oncol"},{"key":"pone.0336767.ref013","doi-asserted-by":"crossref","first-page":"1101861","DOI":"10.3389\/fphar.2023.1101861","article-title":"A real-world disproportionality analysis of apalutamide: data mining of the FDA adverse event reporting system","volume":"14","author":"Z Fang","year":"2023","journal-title":"Front Pharmacol"},{"key":"pone.0336767.ref014","doi-asserted-by":"crossref","first-page":"944342","DOI":"10.3389\/fphar.2022.944342","article-title":"Pulmonary adverse events associated with hypertension in non-small cell lung cancer patients receiving PD-1\/PD-L1 inhibitors","volume":"13","author":"J Chen","year":"2022","journal-title":"Front Pharmacol"},{"issue":"7","key":"pone.0336767.ref015","doi-asserted-by":"crossref","first-page":"617","DOI":"10.2165\/00002018-200730070-00009","article-title":"Standardised MedDRA queries: their role in signal detection","volume":"30","author":"P Mozzicato","year":"2007","journal-title":"Drug Saf"},{"issue":"10","key":"pone.0336767.ref016","doi-asserted-by":"crossref","first-page":"4655","DOI":"10.1007\/s00431-023-05146-2","article-title":"Drug-associated kidney injury in children: a disproportionality analysis of the FDA adverse event reporting system","volume":"182","author":"M Zhang","year":"2023","journal-title":"Eur J Pediatr"},{"issue":"1","key":"pone.0336767.ref017","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1002\/pds.668","article-title":"A comparison of measures of disproportionality for signal detection in spontaneous reporting systems for adverse drug reactions","volume":"11","author":"EP van Puijenbroek","year":"2002","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"6","key":"pone.0336767.ref018","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1002\/pds.677","article-title":"Use of proportional reporting ratios (PRRs) for signal generation from spontaneous adverse drug reaction reports","volume":"10","author":"SJ Evans","year":"2001","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"4","key":"pone.0336767.ref019","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1007\/s002280050466","article-title":"A Bayesian neural network method for adverse drug reaction signal generation","volume":"54","author":"A Bate","year":"1998","journal-title":"Eur J Clin Pharmacol"},{"issue":"6","key":"pone.0336767.ref020","doi-asserted-by":"crossref","first-page":"381","DOI":"10.2165\/00002018-200225060-00001","article-title":"Use of screening algorithms and computer systems to efficiently signal higher-than-expected combinations of drugs and events in the US FDA\u2019s spontaneous reports database","volume":"25","author":"A Szarfman","year":"2002","journal-title":"Drug Saf"},{"issue":"3","key":"pone.0336767.ref021","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1080\/14737140.2021.1852934","article-title":"CDK4\/6 inhibitors in breast cancer: differences in toxicity profiles and impact on agent choice. A systematic review and meta-analysis","volume":"21","author":"CE Onesti","year":"2021","journal-title":"Expert Rev Anticancer Ther"},{"issue":"1","key":"pone.0336767.ref022","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1038\/s41523-023-00520-7","article-title":"The dilemma of selecting a first line CDK4\/6 inhibitor for hormone receptor-positive\/HER2-negative metastatic breast cancer","volume":"9","author":"A Grinshpun","year":"2023","journal-title":"NPJ Breast Cancer"},{"issue":"3","key":"pone.0336767.ref023","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1007\/s40265-020-01461-2","article-title":"Inhibiting CDK4\/6 in Breast Cancer with Palbociclib, Ribociclib, and Abemaciclib: Similarities and Differences","volume":"81","author":"CL Braal","year":"2021","journal-title":"Drugs"},{"issue":"10","key":"pone.0336767.ref024","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1093\/oncolo\/oyac138","article-title":"Targeting CDK4 and 6 in cancer therapy: emerging preclinical insights related to abemaciclib","volume":"27","author":"SA Wander","year":"2022","journal-title":"Oncologist"},{"issue":"1","key":"pone.0336767.ref025","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1007\/s10549-020-05528-2","article-title":"Cyclin-dependent kinase 4 and 6 inhibitors in hormone receptor-positive, human epidermal growth factor receptor-2 negative advanced breast cancer: a meta-analysis of randomized clinical trials","volume":"180","author":"J Li","year":"2020","journal-title":"Breast Cancer Res Treat"},{"key":"pone.0336767.ref026","doi-asserted-by":"crossref","first-page":"1269922","DOI":"10.3389\/fphar.2024.1269922","article-title":"The adverse events of CDK4\/6 inhibitors for HR+\/ HER2- breast cancer: an umbrella review of meta-analyses of randomized controlled trials","volume":"15","author":"D Pu","year":"2024","journal-title":"Front Pharmacol"},{"issue":"2","key":"pone.0336767.ref027","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1158\/1535-7163.MCT-18-0734","article-title":"Intestinal toxicity in rats following administration of CDK4\/6 inhibitors is independent of primary pharmacology","volume":"18","author":"S Thibault","year":"2019","journal-title":"Mol Cancer Ther"},{"key":"pone.0336767.ref028","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.breast.2023.07.003","article-title":"Efficacy of probiotics and trimebutine maleate for abemaciclib-induced diarrhea: a randomized, open-label phase II trial (MERMAID, WJOG11318B)","volume":"71","author":"H Masuda","year":"2023","journal-title":"Breast"},{"key":"pone.0336767.ref029","doi-asserted-by":"crossref","first-page":"1378090","DOI":"10.3389\/fphar.2024.1378090","article-title":"CDK4\/6 inhibitors in drug-induced liver injury: a pharmacovigilance study of the FAERS database and analysis of the drug-gene interaction network","volume":"15","author":"Y She","year":"2024","journal-title":"Front Pharmacol"},{"key":"pone.0336767.ref030","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.toxlet.2023.11.005","article-title":"The cyclin-dependent kinase inhibitor abemaciclib-induced hepatotoxicity: insight on the molecular mechanisms in HepG2\/THP-1 co-culture model","volume":"391","author":"T Boran","year":"2024","journal-title":"Toxicol Lett"},{"issue":"5","key":"pone.0336767.ref031","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1002\/cpt.1296","article-title":"Abemaciclib inhibits renal tubular secretion without changing glomerular filtration rate","volume":"105","author":"JC Chappell","year":"2019","journal-title":"Clin Pharmacol Ther"},{"issue":"6","key":"pone.0336767.ref032","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1007\/s40259-019-00382-1","article-title":"Different cardiotoxicity of palbociclib and ribociclib in breast cancer: gene expression and pharmacological data analyses, biological basis, and therapeutic implications","volume":"33","author":"M Santoni","year":"2019","journal-title":"BioDrugs"},{"issue":"7","key":"pone.0336767.ref033","doi-asserted-by":"crossref","first-page":"796","DOI":"10.7150\/ijms.6048","article-title":"Data mining of the public version of the FDA adverse event reporting system","volume":"10","author":"T Sakaeda","year":"2013","journal-title":"Int J Med Sci"}],"container-title":["PLOS One"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0336767","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,19]],"date-time":"2025-11-19T18:26:33Z","timestamp":1763576793000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0336767"}},"subtitle":[],"editor":[{"given":"Sudhir Kumar","family":"Rai","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2025,11,19]]},"references-count":33,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2025,11,19]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0336767","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,19]]}}}